# Nutraceuticals to Improve Lipid Profile in European Countries

Study · id `cardio:ct-nct01649986` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01649986](<https://clinicaltrials.gov/study/NCT01649986>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01649986

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT01649986. Randomized; quadruple masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2015-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT01649986, source copy `cardio:ctgov-nct01649986-2013-03-07`, retrieved 2026-10-31)
- Start date: 2014-01 (registry gives no type) (ClinicalTrials.gov record NCT01649986, source copy `cardio:ctgov-nct01649986-2013-03-07`, retrieved 2026-10-31)
- Primary completion: 2015-12 (anticipated) (ClinicalTrials.gov record NCT01649986, source copy `cardio:ctgov-nct01649986-2013-03-07`, retrieved 2026-10-31)
- Completion: 2017-12 (anticipated) (ClinicalTrials.gov record NCT01649986, source copy `cardio:ctgov-nct01649986-2013-03-07`, retrieved 2026-10-31)
- Countries: Italy (ClinicalTrials.gov record NCT01649986, source copy `cardio:ctgov-nct01649986-2013-03-07`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01649986-2013-03-07`, retrieved 2026-10-31)

## The registry's words

- Brief title: Nutraceuticals to Improve Lipid Profile in European Countries
- Acronym: PIN
- Condition: Hyperlipidemia
- Intervention (Behavioral): Non-pharmacologic intervention
- Intervention (Drug): Nutraceuticals (Armolipid Plus)
- Lead sponsor: University of Roma La Sapienza
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: University of Roma La Sapienza (`cardio:org-university-of-roma-la-sapienza`)

## Provenance

Content hash: 9206be8624037232cbc5ca8b73db58b1256514227f66b1fb0f2a18aacea35657
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
